These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday.
Silence Therapeutics Plc（纳斯达克股票代码：SLN）周三公布了2023年的亏损。
The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, according to data from Benzinga Pro. Collaboration revenues were £25.4 million versus £17.501 million a year ago. Net loss was £(43.3) million for 2023, compared to a net loss of £(40.5) million in 2022.
根据Benzinga Pro的数据，该公司报告2023年每股亏损为（38.9）便士，低于去年同期的每股亏损（41.9）便士。合作收入为2540万英镑，去年同期为17501万英镑。2023年的净亏损为4,330万英镑，而2022年的净亏损为4,050万英镑。
"We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million," said Rhonda Hellums, Chief Financial Officer of Silence.
Silence首席财务官朗达·海勒姆斯表示：“截至2023年12月，我们的现金状况约为6,880万美元，并在2024年初大幅增加到2亿美元以上。”
Silence also announced topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran in patients with a median baseline Lp(a) of approximately 215 nmol/L.
Silence还公布了正在进行的针对zerlasiran的 ALPACAR-360 2期研究的36周主要数据，该研究针对中位基线Lp（a）约为215 nmol/L的患者。
"We are excited to have multiple programs advancing in the clinic, supported by a substantial cash position that extends our estimated runway into 2026," Hellums added.
Hellums补充说：“我们很高兴在大量现金状况的支持下，临床上有多个项目正在取得进展，这使我们的预计投资期延长至2026年。”
Silence Therapeutics shares fell 3.9% to close at $24.62 on Wednesday.
周三，Silence Therapeutics股价下跌3.9％，收于24.62美元。
These analysts made changes to their price targets on Silence Therapeutics after announcing quarterly results.
这些分析师在公布季度业绩后更改了Silence Therapeutics的目标股价。
- Chardan Capital raised the price target on Silence Therapeutics from $26 to $42. Chardan Capital analyst Keay Nakae maintained a Buy rating.
- Morgan Stanley boosted the price target on Silence Therapeutics from $29 to $45. Morgan Stanley analyst Michael Ulz maintained an overweight rating.
- Chardan Capital将Silence Therapeutics的目标股价从26美元上调至42美元。查丹资本分析师凯伊·纳卡埃维持买入评级。
- 摩根士丹利将Silence Therapeutics的目标股价从29美元上调至45美元。摩根士丹利分析师迈克尔·乌尔兹维持增持评级。